On February 27, we invite you to join us for a Van Andel Institute Scientific Forum on Parkinson’s, Alzheimer’s and Lewy body dementia. During the evening, you will hear from Institute scientists who are working to discover new ways to diagnose and treat Parkinson’s, Alzheimer’s and Lewy body dementia.
This event will also feature a cocktail hour and plated dinner.
Why neurodegenerative science?
In the next decade, the prevalence of neurodegenerative diseases is expected to rise dramatically. Today, 5 million people in the U.S. are living with Alzheimer’s, and by 2060 this number is projected to climb to nearly 14 million. Parkinson’s is also on the rise; by 2020 there will be nearly 1.2 million people living with the disease in the U.S. Although lesser known, Lewy body dementia is the second most common type of progressive dementia after Alzheimer’s disease, and while it is underreported and often misdiagnosed, approximately 1.3 million people in the U.S. are affected by this disease. While these statistics are alarming, there is hope on the horizon. VAI scientists, along with national and international collaborators, are making significant strides toward the development of new diagnostics and therapies that slow or stop disease progression — something no current treatment can accomplish. Join us to learn about the latest advances in this important area of research.
About Van Andel Institute
VAI is an independent biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premiere research and educational institution that supports the work of more than 450 scientists, educators and staff.
Remarks by Peter A. Jones, Ph.D., D.Sc. (hon), Chief Scientific Officer
Remarks by José Brás, Ph.D., Associate Professor, Center for Neurodegenerative Science
Remarks by Rita Guerreiro, Ph.D., Associate Professor, Center for Neurodegenerative Science
Open Q&A facilitated by Brett Holleman, Chief Development Officer
Remarks by David Van Andel, Chairman & CEO
Invocation by Carol Van Andel, Executive Director of the David & Carol Van Andel Family Foundation
Peter A. Jones, Ph.D., D.Sc. (hon)
Peter A. Jones, Ph.D., D.Sc. (hon), is a pioneer in epigenetics, a growing field that explores how genes are regulated and for developing therapies for cancer and other diseases. His discoveries have helped usher in an entirely new class of drugs that have been approved to treat blood cancer and are being investigated in other tumor types. Jones is a past president of the American Association for Cancer Research, a Fellow of the AACR Academy, a Fellow of the American Association for the Advancement of Science and was recently elected to the National Academy of Sciences.
José Brás, Ph.D.
José Brás, Ph.D. is a world-leading molecular geneticist whose research focuses on how variations in our genes impact the onset and progression of neurodegenerative diseases such as Parkinson’s, Alzheimer’s and dementia with Lewy bodies. He is an associate professor at Van Andel Institute.
Rita Guerreiro, Ph.D.
Rita Guerreiro, Ph.D. is an internationally recognized leader in neurogenetics who studies genomic contributors to neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. She is an associated professor at Van Andel Institute.
Contact Sarah Rollman at 616.234.5712 or via email for more information or to become an event sponsor.